Orchid Pharma Ltd

Orchid Pharma Ltd has witnessed a significant shift in its valuation parameters, moving from an expensive to a very expensive rating, driven primarily by a sharp rise in its price-to-earnings (P/E) ratio to 129.78. Despite this valuation surge, the company’s recent returns have been mixed, with strong short-term gains contrasting with underperformance over longer horizons relative to the Sensex.

Orchid Pharma Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 13 Feb 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 01 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Orchid Pharma Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in price momentum and technical indicators, reflecting a complex market sentiment. Despite a recent day gain of 3.39%, the stock remains under pressure with a strong sell rating and mixed signals from key technical tools such as MACD, RSI, and moving averages.

Orchid Pharma Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 13 February 2025, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics discussed below are based on the company’s current position as of 20 April 2026, providing investors with the latest insights into its performance and valuation.

Orchid Pharma Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 13 Feb 2025, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics presented here are based on the company’s current position as of 09 April 2026, providing investors with the latest insights into its performance and valuation.

Orchid Pharma Ltd commenced trading on 8 Apr 2026 with a notable gap up, opening at a price reflecting an 8.42% increase from its previous close. This strong start underscores positive market sentiment despite the company’s current 'Strong Sell' rating by MarketsMOJO, highlighting a complex interplay between technical factors and market dynamics.

The Sensex gained 2.7% on 1 Apr 2026, yet Orchid Pharma Ltd outpaced the broader market with a 7.21% intraday rally, reaching a high of Rs 499. This 1.52 percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers highlights a distinctly stock-specific surge rather than a market-wide lift.

Despite a broader market rebound, Orchid Pharma Ltd has succumbed to renewed selling pressure, hitting a fresh 52-week low of Rs 483 on 30 Mar 2026. This decline extends a recent losing streak that has dragged the stock down by 6.85% over two sessions, underscoring persistent headwinds for the small-cap pharmaceutical player.

Orchid Pharma Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 13 February 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 29 March 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Orchid Pharma Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 13 Feb 2025. However, the analysis below reflects the stock’s current position as of 18 March 2026, incorporating the latest fundamentals, returns, and financial metrics to provide investors with an up-to-date perspective.

Orchid Pharma Ltd’s shares declined to a fresh 52-week low of Rs.488.8 on 9 March 2026, marking a significant milestone in the stock’s ongoing downward trajectory. The pharmaceutical company’s stock has underperformed its sector and broader market indices, reflecting persistent pressures on its financial and operational metrics.

Orchid Pharma Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 13 Feb 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 07 March 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Orchid Pharma Ltd experienced a significant intraday decline on 4 Mar 2026, touching a low of Rs 550, reflecting an 8.3% drop from previous levels. The stock underperformed its sector and broader market indices, continuing a downward trend amid persistent selling pressure and subdued market sentiment.

Orchid Pharma Ltd commenced trading today with a significant gap down, opening at an 18.85% lower price compared to its previous close, reflecting heightened market apprehension following recent developments. The stock hit a new 52-week low of Rs.503, underperforming its sector and broader indices amid sustained selling pressure.

Orchid Pharma Ltd’s shares touched a fresh 52-week low of Rs.503 today, marking a significant decline amid ongoing pressures in the Pharmaceuticals & Biotechnology sector. The stock has underperformed both its sector and the broader market, reflecting persistent challenges in financial performance and valuation metrics.

Orchid Pharma Ltd has witnessed a notable shift in its valuation parameters, moving from a 'very expensive' to an 'expensive' rating, reflecting a subtle but significant change in price attractiveness. Despite this adjustment, the stock remains priced at a premium relative to its peers and historical averages, raising concerns for investors amid a challenging pharmaceutical sector backdrop.

Orchid Pharma Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 13 February 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.